Clinical Trial Update: Study of XB002 in Subjects With Solid Tumors (JEWEL-101) [Phase 1]

View source ↗

Summary

JEWEL-101 is a Phase 1 trial of XB002 in patients with solid tumors, covering multiple indications. The study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer
• Cervical Cancer
• Endometrial Cancer
• Esophageal Squamous Cell Carcinoma
• Non-small Cell Lung Cancer
• Pancreatic Cancer
• Squamous Cell Carcinoma of the Head and Neck
• Triple-negative Breast Cancer

Drugs mentioned

• XB002

Snippet

Sponsor: Exelixis | Conditions: Non Small Cell Lung Cancer, Cervical Cancer | Phase 1 | Status: COMPLETED